UltraPlex 1-Step ToughMix
Tough-tested, multiplex, 1-step real time PCR
Features & Benefits
- 4X concentrated master mix allows greater flexibility with dilute samples - as little as 1 pg of total RNA
- Multiplexing capable with up to 5 targets
- Tough-tested for applications where PCR inhibition from template impurities may be a concern, such as: crude extracts, clinical specimens, or environmental samples.
- Temperature stabilized master mix enables convenient reaction setup at ambient room temperature
UltraPlex 1-Step ToughMix is intended for molecular biology applications. This product is not intended for the diagnosis, prevention or treatment of a disease.
UltraPlex 1-Step ToughMix is a ready-to-use, 4X concentrated master mix 1-step reverse transcription and real-time quantitative PCR (RT-qPCR) of RNA templates using probe-based detection methods. First-strand cDNA synthesis and PCR amplification are carried out in the same tube without opening between steps. Optimized to deliver highly sensitive quantification of RNA viruses or low abundance RNA targets in uni- or highly multiplexed RNA detection assays, this reagent chemistry is optimized to deliver maximum assay sensitivity, precision and reproducibility with miniaturized reaction volumes and either conventional or accelerated thermal cycling protocols. UltraPlex 1-Step ToughMix contains all required components for RT-qPCR except RNA template and probe and is compatible with all dual-labeled probe chemistries.
UltraPlex 1-Step ToughMix (Low ROX/ ROX) (4X), contains:
- 4X reaction buffer containing optimized titrations of qPCR-grade dATP, dCTP, dGTP, dTTP, and magnesium.
- Ultra-pure recombinant proteins: qScript XLT reverse transcriptase, RNase inhibitor protein, and AccuStart II hot-start Taq DNA polymerase.
- Proprietary stabilizers additives and optimized ROX passive reference dye (if applicable).
Storage & HandlingStore components in a constant temperature freezer at -25°C to -15°C protected from light upon receipt. For lot specific expiry date, refer to package label, Certificate of Analysis or Product Specification Form.
Repeated freezing and thawing does not affect RT-qPCR performance.
- Applied Biosystems 5700
- Applied Biosystems 7000
- Applied Biosystems 7300
- Applied Biosystems 7700
- Applied Biosystems 7900
- Applied Biosystems 7900HT
- Applied Biosystems 7900 HT Fast
- Applied Biosystems StepOne™
- Applied Biosystems StepOnePlus™
- Applied Biosystems 7500
- Applied Biosystems 7500 Fast
- Stratagene Mx3000P®
- Stratagene Mx3005P™
- Stratagene Mx4000™
- Applied Biosystems ViiA 7
- Applied Biosystems QuantStudio™
- Agilent AriaMx
- Douglas Scientific IntelliQube®
Bio-Rad iCycler iQ systems
- Quantabio Q
- BioRad CFX
- Roche LightCycler 480
- QIAGEN Rotor-Gene Q
- BioRad iCycler iQ™
- BioRad MyiQ™
- BioRad iQ™5
Related ResourcesProduct FlyersProduct ManualsPublicationsThe effect of increased inoculum on oral rotavirus vaccine take among infants in Dhaka, Bangladesh: A double-blind, parallel group, randomized, controlled trialClick here to see all PublicationsBenjamin Lee, Vaccine - 2020AbstractBackground Oral, live-attenuated rotavirus vaccines suffer from impaired immunogenicity and efficacy in low-income countries. Increasing the inoculum of vaccine might improve vaccine response, but this approach has been inadequately explored in low-income countries. Methods We performed a double-blind, parallel group, randomized controlled trial from June 2017 through June 2018 in the urban Mirpur slum of Dhaka, Bangladesh to compare vaccine take (primary outcome) among healthy infants randomized to receive either the standard dose or double the standard dose of oral Rotarix (GlaxoSmithKline) vaccine at 6 and 10 weeks of life. Infants with congenital malformations, birth or enrollment weight <2000 gm, known immunocompromising condition, enrollment in another vaccine trial, or other household member enrolled in the study were excluded. Infants were randomized using random permuted blocks. Vaccine take was defined as detection of post-vaccination fecal vaccine shedding by real-time reverse transcription polymerase chain reaction with sequence confirmation or plasma rotavirus-specific immunoglobulin A (RV-IgA) seroconversion 4 weeks following the second dose. Results 220 infants were enrolled and randomized (110 per group). 97 standard-dose and 92 high-dose infants completed the study per-protocol. For the primary outcome, no significant difference was observed between groups: vaccine take occurred in 62 (67%) high-dose infants versus 69 (71%) standard-dose infants (RR 0.92, 95% CI 0.67–1.24). However, in post-hoc analysis, children with confirmed vaccine replication had significantly increased RV-IgA responses, independent of the intervention. No significant adverse events related to study participation were detected. Conclusions Administration of double the standard dose of an oral, live-attenuated rotavirus vaccine (Rotarix) did not improve vaccine take among infants in urban Dhaka, Bangladesh. However, improved immunogenicity in children with vaccine replication irrespective of initial inoculum provides further evidence for the need to promote in-host replication and improved gut health to improve oral vaccine response in low-income settings. ClinicalTrials.gov: NCT02992197.Safety Data Sheets (SDS)CofA (PSF)PSF-95166-500-Lot#021890PSF-95166-500-Lot#021891PSF-95166-500-Lot#022969PSF-95167-100-Lot#022422PSF-95167-500-Lot#022423PSF-95168-500-Lot# 022416PSF-95168-100-Lot#023967PSF-95168-500-Lot#023968PSF-95166-500-Lot#024085PSF-95168-500-Lot#024522PSF-95168-500-Lot#024893PSF-95166-100-Lot#025390PSF-95166-500-Lot#025391PSF-95168-500-Lot#025386PSF-95167-100-Lot#025466PSF-95168-500-Lot#025801PSF-95166-100-Lot#026369PSF-95166-500-Lot#026370PSF-95168-100-Lot#026975PSF-95168-100-Lot#027045PSF-95166-100-Lot#027588PSF-95166-500-Lot#027589PSF-95168-500-Lot#027906PSF-95166-500-Lot#028185PSF-95166-100-Lot# 028736PSF-95166-500-Lot#028737PSF-95168-500-Lot#028877PSF-95168-100-Lot#029530PSF-95168-500-Lot#029531PSF-95166-01K-Lot#029948PSF-95167-100-Lot#029689PSF-95167-100-Lot#030000PSF-95167-500-Lot#030001PSF-95166-100-Lot#030094PSF-95168-100-Lot#030046PSF-95166-500-Lot#030294PSF-95167-500-Lot#030312PSF-95166-01K-LOT#66139974PSF-95168-500-LOT#66139972PSF-95166-100-LOT#66140414PSF-95166-500-Lot#028737PSF-95166-100-LOT#66142496PSF-95168-100-LOT#66141489PSF-95168-500-LOT#66141490PSF-95166-01K-LOT#66147370PSF-95166-500-LOT#66148043PSF-95166-500-LOT#66148043PSF-95166-01K-LOT#66148967PSF-95166-01K-LOT#66152573PSF-95166-500-LOT#66153258PSF-95168-100-LOT#66153260PSF-95166-100-LOT#66154306PSF-95168-500-LOT#66154460PSF-95166-100-LOT#66155755PSF-95166-500-LOT#66155754PSF-95167-100-LOT#66155757PSF-95168-100-LOT#66155955PSF-95168-500-LOT#66155760PSF-95166-01K -LOT#66157161PSF-95166-500-LOT#66157160PSF-95168-100-LOT#66157825PSF-95168-500-LOT#66157129PSF-95166-100-LOT#66158195PSF-95166-500 Lot# 66158194PSF-95167-100 Lot66158250